Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07141329
PHASE2
SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures
Sponsor: Supernus Pharmaceuticals, Inc.
View on ClinicalTrials.gov
Summary
This is a Phase 2b open-label extension study to evaluate the long-term safety and efficacy of SPN-817.
Official title: An Open-Label Extension, One-Year, Safety, and Efficacy Study of SPN-817 in Adults With Focal Onset Seizures
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2025-07-30
Completion Date
2027-12-31
Last Updated
2025-10-10
Healthy Volunteers
No
Conditions
Interventions
DRUG
SPN-817
SPN-817 starting at 0.25 mg bid up to 4.00 mg bid
Locations (1)
Medsol Clinical Research Center
Port Charlotte, Florida, United States